Table 3.
Event Rate and Risk of S/SE, Bleeding, and Death in Anticoagulated AF Patients
| Event Rate/100 Person‐Years (95% CI) | Crude | Adjusteda | Competing Risk | |||||
|---|---|---|---|---|---|---|---|---|
| NOAC | Warfarin | HR (95% CI) | P Value | HR (95% CI) | P Value | HR (95% CI) | P Value | |
| Normal liver function (n=5818) | ||||||||
| S/SE | 5.52 (4.99–6.11) | 8.08 (7.45–8.77) | 0.78 (0.68–0.91) | <0.001 | 0.75 (0.65–0.88) | <0.001 | 0.75 (0.64–0.88) | <0.001 |
| MB | 1.23 (1.01–1.50) | 2.16 (1.87–2.50) | 0.86 (0.65–1.14) | 0.292 | 0.83 (0.62–1.11) | 0.201 | 0.81 (0.61–1.09) | 0.162 |
| GIB | 1.27 (1.04–1.54) | 1.23 (1.02–1.49) | 1.39 (1.02–1.90) | 0.039 | 1.36 (0.99–1.88) | 0.059 | 1.33 (0.95–1.85) | 0.094 |
| Death | 2.80 (2.45–3.20) | 3.65 (3.26–4.08) | 0.70 (0.61–0.80) | <0.001 | 0.69 (0.60–0.80) | <0.001 | ||
| ILF (n=633) | ||||||||
| S/SE | 8.80 (6.50–11.90) | 6.92 (5.46–8.78) | 0.99 (0.65–1.52) | 0.976 | 0.77 (0.49–1.22) | 0.271 | 0.72 (0.46–1.15) | 0.169 |
| MB | 3.86 (2.52–5.92) | 3.83 (2.83–5.19) | 1.14 (063–2.08) | 0.658 | 1.31 (0.70–2.48) | 0.399 | 1.19 (0.60–2.35) | 0.622 |
| GIB | 3.64 (2.35–5.65) | 2.17 (1.47–3.22) | 1.49 (0.79–2.81) | 0.218 | 1.68 (0.86–3.29) | 0.132 | 1.44 (0.75–2.75) | 0.272 |
| Death | 9.80 (7.43–12.93) | 12.07 (10.02–14.53) | 0.68 (0.53–0.87) | 0.002 | 0.64 (0.49–0.83) | <0.001 | ||
AF indicates atrial fibrillation; CI, confidence interval; GIB, gastrointestinal bleeding; HR, hazard ratio; ILF, impaired liver function; MB, major bleeding; NOAC, non–vitamin K antagonist oral anticoagulant; S/SE, stroke or systemic embolism.
a
Adjusted for age, sex, hypertension, diabetes mellitus, chronic kidney disease, history of myocardial infarction, history of ischemic heart disease, history of systemic embolism, history of peripheral vascular disease, history of transient ischemic attack, history of stroke, history of heart failure, statins, amiodarone, anticonvulsants, NSAIDs, aspirin, clopidogrel, and ticagrelor.